Lance K. Heilbrun

10.0k total citations
236 papers, 7.8k citations indexed

About

Lance K. Heilbrun is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lance K. Heilbrun has authored 236 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 84 papers in Pulmonary and Respiratory Medicine and 59 papers in Molecular Biology. Recurrent topics in Lance K. Heilbrun's work include Prostate Cancer Treatment and Research (36 papers), Colorectal Cancer Treatments and Studies (24 papers) and Cancer Treatment and Pharmacology (18 papers). Lance K. Heilbrun is often cited by papers focused on Prostate Cancer Treatment and Research (36 papers), Colorectal Cancer Treatments and Studies (24 papers) and Cancer Treatment and Pharmacology (18 papers). Lance K. Heilbrun collaborates with scholars based in United States, Canada and United Kingdom. Lance K. Heilbrun's co-authors include Grant N. Stemmermann, Abraham M. Y. Nomura, Richard D. Wasnich, John M. Vogel, Zora Djurić, Philip D. Ross, Anthony F. Shields, Ulka N. Vaishampayan, Katsuhiko Yano and Mark M. Zalupski and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Lance K. Heilbrun

236 papers receiving 7.5k citations

Peers

Countries citing papers authored by Lance K. Heilbrun

Since Specialization

Citations

This map shows the geographic impact of Lance K. Heilbrun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lance K. Heilbrun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lance K. Heilbrun more than expected).

Fields of papers citing papers by Lance K. Heilbrun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lance K. Heilbrun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lance K. Heilbrun. The network helps show where Lance K. Heilbrun may publish in the future.

Co-authorship network of co-authors of Lance K. Heilbrun

This figure shows the co-authorship network connecting the top 25 collaborators of Lance K. Heilbrun. A scholar is included among the top collaborators of Lance K. Heilbrun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lance K. Heilbrun. Lance K. Heilbrun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer 2024 ·Cancer Research Communications ·Elisabeth I. Heath, Archana Thakur, Wei Chen, Clara Hwang, Channing J. Paller, Frank C. Cackowski, Julie L. Boerner, Lance K. Heilbrun, (unknown), Dana L. Schalk, (unknown), (unknown), (unknown), Daryn Smith, Ulka N. Vaishampayan, Brenda Dickow, Lawrence G. Lum	3
2	Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counselling 2019 ·Urologic Oncology Seminars and Original Investigations ·Kevin Ginsburg, Adam Cole, Michael E. Silverman, (unknown), Daryn Smith, Lance K. Heilbrun, Dongping Shi, Rohit Mehra, Wael Sakr, Todd M. Morgan, Michael L. Cher	10
3	Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients 2018 ·Clinical Cancer Research ·Nader Sanai, Jing Li, Julie L. Boerner, (unknown), Jianmei Wu, Seongho Kim, (unknown), Shwetal Mehta, Harshil Dhruv, Lance K. Heilbrun, Michael E. Berens, Patricia LoRusso	61
4	Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer 2018 ·Clinical Cancer Research ·Ulka N. Vaishampayan, Izabela Podgorski, Lance K. Heilbrun, Jawana M. Lawhorn‐Crews, (unknown), Julie L. Boerner, (unknown), Daryn Smith, Elisabeth I. Heath, Joseph A. Fontana, Anthony F. Shields	3
5	Transcriptional Regulation of CXCR4 in Prostate Cancer: Significance of TMPRSS2-ERG Fusions 2013 ·Molecular Cancer Research ·Rajareddy Singareddy, Louie Semaan, M. Katie Conley‐LaComb, (unknown), Katelyn Powell, Matthew K. Iyer, Daryn Smith, Lance K. Heilbrun, Dongping Shi, Wael Sakr, Michael L. Cher, Sreenivasa R. Chinni	35
6	Impact of Race, Age, and Socioeconomic Status on Participation in Pancreatic Cancer Clinical Trials 2010 ·Pancreas ·Bassel F. El‐Rayes, (unknown), Richard K. Severson, Khaldoun Almhanna, Philip A. Philip, Anthony F. Shields, Mark M. Zalupski, Lance K. Heilbrun	18
7	Retrospective review of cancer patients ≥80 years old treated with chemotherapy at a comprehensive cancer center 2008 ·Critical Reviews in Oncology/Hematology ·Minsig Choi, (unknown), Lance K. Heilbrun, Daryn Smith, Shirish M. Gadgeel	5
8	Mature Results of a Phase II Trial of Gemcitabine/Paclitaxel Given Every 2 Weeks in Patients with Advanced Non–Small-Cell Lung Cancer 2007 ·Clinical Lung Cancer ·Antoinette J. Wozniak, (unknown), Lance K. Heilbrun, Ömer Küçük, Shirish M. Gadgeel, Gregory P. Kalemkerian, Raghu Venkatramanamoorthy, Michael Kraut	3
9	Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Shirish M. Gadgeel, John C. Ruckdeschel, Elisabeth I. Heath, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Antoinette J. Wozniak	50
10	Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma 2007 ·Anti-Cancer Drugs ·Ulka N. Vaishampayan, Lance K. Heilbrun, (unknown), Daryn Smith, Lawrence E. Flaherty	9
11	P2-220: Radiation pneumonitis (RP) in lung cancer patients treated with chemotherapy (CT) and thoracic radiation (TR): Retrospective analyses of patients treated at a comprehensive cancer center 2007 ·Journal of Thoracic Oncology ·Prakash Vishnu, Sridhar Srinivasan, (unknown), Andrew T. Turrisi, Lance K. Heilbrun, (unknown), (unknown), Ayman O. Soubani, Shirish M. Gadgeel	1
12	Non‐bacterial infections in allogeneic non‐myeloablative stem cell transplant recipients 2007 ·Transplant Infectious Disease ·(unknown), (unknown), Muneer H. Abidi, (unknown), (unknown), Lance K. Heilbrun, Daryn Smith, George Alangaden, P.H. Chandrasekar	9
13	Pilot study of intraoperative chemotherapy with cisplatin and 5‐fluorouracil in patients with advanced squamous cell carcinoma of the head and neck 2006 ·Head & Neck ·(unknown), (unknown), Ömer Küçük, Lance K. Heilbrun, (unknown), Hakan Korkmaz, (unknown), John R. Jacobs	1
14	A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor 2006 ·Investigational New Drugs ·Amin M. Alousi, Ramesh Boinpally, Richard Wiegand, Ralph E. Parchment, Shirish M. Gadgeel, Lance K. Heilbrun, (unknown), Pamela DeLuca, Patricia LoRusso	23
15	Methods to Increase Fruit and Vegetable Intake With and Without a Decrease in Fat Intake: Compliance and Effects on Body Weight in the Nutrition and Breast Health Study 2002 ·Nutrition and Cancer ·Zora Djurić, (unknown), (unknown), Virginia Uhley, Samir Lababidi, Chandice Covington, David M. Klurfeld, Michael S. Simon, Ömer Küçük, Lance K. Heilbrun	55
16	Comparison of Dietary Assessment Methods in a Low-Fat Dietary Intervention Program 2001 ·Nutrition and Cancer ·Michael S. Simon, Samir Lababidi, (unknown), Virginia Uhley, (unknown), (unknown), David M. Klurfeld, Lance K. Heilbrun	6
17	Growth inhibition of MCF-7 and MCF-10A human breast cells by α-tocopheryl hemisuccinate, cholesteryl hemisuccinate and their ether analogs 1997 ·Cancer Letters ·Zora Djurić, Lance K. Heilbrun, Samir Lababidi, (unknown), Marc W. Fariss	48
18	A randomized trial of a low‐fat dietary intervention in women at high risk for breast cancer 1997 ·Nutrition and Cancer ·Michael S. Simon, Lance K. Heilbrun, (unknown), Cynthia Kresge, (unknown), (unknown), Frederick A. Valeriote, Silvana Martino	44
19	5-fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer 1991 ·Cancer ·Lawrence E. Flaherty, Antoinette J. Wozniak, Bruce G. Redman, Michael Kraut, Silvana Martino, Lance K. Heilbrun, Manuel Valdivieso	6
20	Characteristics of respondents and nonrespondents in a prospective study of osteoporosis 1991 ·Journal of Clinical Epidemiology ·Lance K. Heilbrun, Philip D. Ross, Richard D. Wasnich, Katsuhiko Yano, John M. Vogel	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact